This is a 51-year-old female with lobular carcinoma of the breast, estrogen receptor (ER) positive, progesterone receptor (PR) negative, metastatic to bone. The patient is status post adjuvant chemotherapy and radiation for T3 N2 M0 stage IIIA disease, originally diagnosed in 1995. The patient had 3 years of hormonal therapy with tamoxifen, but in 1999, CA 27, 29 levels increased, and a bone scan was then suspicious for metastatic disease. The patient was treated with aromatase inhibitors; however a follow-up bone scan revealed progression of disease, and the patient was subsequently started on Aredia. Past medical history is significant for hypothyroidism. Review of systems reveals fatigue, anorexia, and a weight loss of 12 pounds, which is approximately 10% of usual body weight. The patient has pain management issues with resulting limitation in physical activity. Labs in September 2000 revealed anemia, leukopenia, and elevated liver enzymes (AST and LDH); CA 27, 29 was significantly elevated at 1822. The immune panel reveals a low percentage of T helper cells. Current symptoms suggest progression of bone metastases, possibly causing sacral nerve root involvement and back pain, as well as possible orthostatic hypotension, intermittent claudication, hypothyroidism, not well controlled with current therapy, and menopausal symptoms.
Diagnostic Assessment
There is no mention of the patient's HER2/neu status. If the original tissues blocks of the surgical specimen can be obtained, HER2/neu staining would be a useful indicator. HER2/neu is positive in approximately 25% to 30% of women with metastatic breast cancer, making treatment with Herceptin, the humanized monoclonal antibody that binds to the HER2/neu receptor, a possibility. First approved for use in 1998, Herceptin is indicated for use as a single agent or in combination with paclitaxel, in the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein. When added to chemotherapy, Herceptin improves antitumor efficacy as measured by time to progression, response rate, and survival. 1 Other combinations of Herceptin and chemotherapy have been investigated, with data suggesting considerable activity with either weekly taxol or when combined with navelbine.
The patient has a past medical history of hypothyroidism. Although the exact mechanism for the demonstrated association between diseases of the thyroid and breast cancer remains unknown, there is at least the possibility that the presence of thyroid abnormalities may influence breast cancer. A direct correlation between degree of thyroid enlargement and breast tumor staging has been found. 2 A thyroid panel should be included in the complete work up of this patient.
The patient's abnormal lab values from September 2000 are of some concern. Since the patient has not been on myelosuppressive chemotherapeutic agents in over 3 years, the anemia and neutropenia suggest that a bone marrow aspiration and biopsy, as previously recommended, would be useful to rule out bone marrow infiltration with tumor. In addition, there is no clear indication of the date of the most recent CT scans; therefore other sites of metastatic disease, including the liver, cannot be ruled out.
The results of the immune panel are of some interest in this case. Absolute T-helper cells encompass CD4 and CD3 cells, and normal ranges are from 398-1535. The patient's percent of CD3 cells are low at 58% (range 63-84), while the absolute number falls well within the normal range at 1566 (range 724-2409). CD4/CD8 ratio in this patient is on the low end of normal at 0.96 (range 0.8-3.3). At least one study looked at lymphocytes from 48 patients with breast cancer. The difference between healthy donors and Stage IV breast cancer patients was statistically significant (P = 0.01). The average CD4/CD8 value in the group of breast cancer patients with lymph node or distant metastases was lower than that of patients without metastases, but the difference was not statistically significant. 3 The patient has incurred a 12-pound weight loss, roughly 10% of usual body weight. A monthly evaluation is indicated using the Patient-Generated Subjective Global Assessment (PG-SGA) of nutritional status, which has been well validated as a proactive standardized interventional approach. 4 A 3-compartment body composition analysis to determine lean body cell mass is also indicated, as Cheney et al investigated changes in weight associated with treatment for breast cancer and determined that regardless of weight gain or loss, women were likely to lose lean body mass and gain fat mass during treatment for breast cancer. 5 Progressive weight loss, in the form of lean body mass, is responsible not only for a poor quality of life and poor response to chemotherapy, but also for a shorter survival time than is found in patients with comparable tumors without weight loss. 6 While this patient's serum albumin and protein were within the normal range, further evaluation and monitoring with serum transferrin and prealbumin is recommended, as these are more sensitive indicators of protein deficiency. If the values decrease at a later date, a cachexia panel looking at TNF alpha and IL-6 may provide more prognostic data and indicate the need for more aggressive intervention.
Recommendations

Conventional Approaches
Several second-line chemotherapy regimens may be appropriate for this patient. Results from phase III studies in which individual studies with docetaxel and paclitaxel have been compared with standard therapies indicate that docetaxel is the most active single agent in metastatic breast cancer. 7 A phase-II multicenter study of sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines showed an overall response rate of 57%, and 5% of patients had stable disease. 8 Median time to progression and survival was 10.1 and 17.1 months. Another phase-II multicenter trial showed similar results, with an overall response rate of 53.3% and median time to progression of 9.8 months. 9 The investigators concluded that docetaxel and vinorelbine is an effective and well-tolerated regimen for the treatment of metastatic breast cancer, particularily in patients previously treated with anthracyclines.
A phase I/II-trial investigating the activity of ifosfamide/carboplatin/etoposide given over 3 days (mini-ICE) showed that this regimen has activity against anthracycline-refractory metastatic breast cancer as well. 10 
Nutrition
The patient eats meat about 3 times per week, which may not provide an adequate protein intake. With the combination of the data collected from the PG-SGA and the body composition analysis documenting lean body cell mass, individual dietary suggestions could intelligently be formulated, including recommended daily intake of protein, consisting of organic foods, wild game, poultry, and fish. Red meat is not recommended. If lean body cell mass is significantly decreased, increased caloric and protein intake alone may not reverse the condition. The patient is experiencing anorexia, but often appetite stimulants, such as cyproheptadine, medroxyprogesterone acetate, and megestrol acetate do not significantly improve lean body mass. As the patient loses lean body cell mass, fatigue often ensues. Tumor products, such as lipidmobilizing factor, which directly stimulates lipolysis in a cyclic AMP-dependent manner and increases energy expenditure, and proteolysis-inducing factor, which initiates protein catabolism in skeletal muscle, are both attenuated by eicosapentaenoic acid (EPA), which is effective at preventing loss of skeletal muscle in cancer patients. 11 Exercise Cancer-induced skeletal muscle wasting may occur despite normal food intake and cannot always be prevented by nutritional supplementation. While evidence suggests that endurance and exercise ameliorate cancer-related fatigue and attenuate muscle wasting associated with a variety of catabolic conditions, these effects on cancer-induced muscle wasting have not been adequately studied. 12 However, many similarities exist between the muscle wasting associated with cancer and that of HIV. As with cancer, HIV is a chronic condition in which unintentional loss of weight and lean body mass is a major cause of morbidity and mortality. The effect of physical training in HIV-positive patients via progressive resistance training (PRT) was found to improve functional status, measured using a validated Physical Function scale, in both wasted and nonwasted HIV-positive patients. The subjects trained 3 times per week for 8 weeks, followed by 8 weeks of usual activity. Lean body mass increased 2.3% in the nonwasted and 5.3% in the wasted patients. In addition, both resistance and endurance exercise augment endogenous growth hormone levels, decrease depression, enhance self-esteem, and may improve immune response. 13, 14 At least one randomized double-blind trial has shown that physical therapy increases total body weight, lean body mass, exercise capacity, and quality of life. 15 Although these studies were completed with HIV-positive subjects, the similarities regarding cachexia and muscle wasting are common in patients with cancer. Thus, it is recommended that patients partake in a physical exercise program to receive the benefits listed above.
Review of Nutritional and Botanical Supplements
Isoflavone/Ipriflavone
The literature regarding the use of isolated isoflavone extracts by breast cancer patients is controversial. To date, there has been no published data on the use of isoflavone extracts in breast cancer patients. The only randomized double-blind clinical trial with breast cancer survivors examined the effectiveness of soy for the treatment of hot flashes and found that there was no suggestion that the soy product was any more effective in reducing hot flashes than the placebo. 16 Recent research indicates that soy protein isolates containing increasing amounts of genistein stimulate the growth of estrogen-dependent breast cancer (MCF-7) cells in vivo in a dose-dependent manner. 17 While there has been in vitro data indicating that genistein exhibits a biphasic effect, stimulating cellular proliferation of MCF-7 cells at low concentrations and markedly inhibiting cellular proliferation at high concentrations, the inhibitory effect is not ER-dependent and is probably related to inhibition of the tyrosine kinase activity of growth factor receptors. Moreover, in intact (not ovariectomized) mice fed estrogen, genistein inhibits tumor growth. 19 At low concentrations, genistein behaves like a competitive inhibitor for the binding site of estradiol (E2) to ER and slightly inhibits cellular proliferation, since genistein has a lower activity than E2.
The final effect on breast tissue depends on the intramammary genistein and estradiol concentrations, which in turn, depend on individual phytoestrogen metabolism, which can vary markedly. 20 Therefore, it is impossible to predict whether the final effect of isoflavones on breast tissue will be stimulatory (which may be due to low concentrations of local E2), slightly inhibitory (which may be due to competitive inhibition of the binding of E2 to ER), or markedly inhibitory (which may be due to inhibition of tyrosine kinase). In a breast cancer patient with ER positive disease, the effects of supplementing isoflavones are unknown at this time and thus not recommended.
While ipriflavone makes sense from a bone mineralization perspective, research is lacking as far as its use in breast cancer patients. Ipriflavone is theorized to be devoid of direct estrogenic properties but active in potentiating the effects of estrogen on bone tissue. Petilli et al investigated the possible interactions of ipriflavone and its 4 main in vivo metabolites with the estrogen receptor in human preosteoclastic cell line FLG 29.1, and in parallel experiments, MCF-7 cells were also analyzed. Ipriflavone and its metabolites did not induce ER-dependent gene expression in FLG 29.1 and MCF-7 cells transfected with a reporter gene and an estrogen response element. 21 However, Kuiper et al investigated the interaction of estrogenic chemicals and phytoestrogens with ER alpha and beta and found that phytoestrogens, including ipriflavone, have varying binding affinities for ER alpha and especially ER beta and concluded that they may trigger many of the biological responses evoked by physiological estrogens. 22 The data is limited and inconclusive for ipriflavone and warrants further investigation before it can be recommended for ER positive breast cancer patients.
Indolplex
Indolplex contains diindolylmethane (DIM), the active metabolite of indole-3-carbinol (I-3-C), which has been shown to induce the 2-hydroxylation of estrogens, which manipulates estrogen metabolism and may decrease breast cancer risk. DIM has also been shown to inhibit proliferation of human breast cancer cells at concentrations achievable through supplementation with I-3-C. 23 Incubation of breast cancer cells with DIM has been found to promote apoptosis, independent of p53. 24 I-3-C has also been shown to significantly inhibit cell adhesion, spreading, and invasion associated with an up-regulation of PTEN (a tumor suppressor gene) and E-cadherin (a regulator of cell-cell adhesion) expression in T47-D human breast cancer cells. Therefore, I-3-C exhibits anticancer activities by suppressing breast tumor cell growth and metastatic spread. 25 
Recommended Additions
Vitamin A Vitamin A in combination with tamoxifen shows benefit in advanced metastatic breast cancer. 26 Vitamin A also produces a dose-dependent decrease in human breast cancer cell lines in vitro and in athymic mice.
Vitamin E
The proliferation of human breast cancer cells has been shown to be inhibited by vitamin E succinate (VES). 28 
Melatonin
The oncostatic action of melatonin is very complex and involves different mechanisms, including modulation of endocrine and immune systems and direct antiproliferative action. Melatonin has repeatedly been shown to inhibit the proliferation of MCF-7 human breast cancer cells. 9 In addition, melatonin has been shown to reduce the incidence of weight loss in metastatic cancer patients. 30 
Green Tea Extract
The polyphenols contained in green tea have a number of anticancer effects, including anti-angiogenesis, protein kinase C inhibition, TNF-alpha inhibition, and up-regulation of p53. Studies also indicate inhibition of tumor growth in MCF-7 breast cancer cell lines and animal models. 31 
